Skip to content

Effect of Colony Stimulating Factor on Poor Endometrial Development During IVF

G-CSF and Endometrial Growth, Embryo Implantation and Pregnancy Following FET or Donor ET

Status
Terminated
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01202643
Enrollment
12
Registered
2010-09-16
Start date
2010-09-30
Completion date
2013-02-28
Last updated
2019-07-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility, Female

Keywords

Thin Endometrium, Asherman's Syndrome, Endometrial Scarring

Brief summary

The purpose of this study is to investigate the effect of G-CSF on endometrial thickness in women who have failed reaching minimal endometrial thickness by standard treatments, to assess how many reach embryo transfer and what implantation and pregnancy rates are in comparison to control patients. The study will be conducted in women undergoing transfer of previously cryopreserved embryos or undergoing transfer of embryos from donor eggs.

Detailed description

Objective: To investigate the effect of treatment with CSF : A placebo controlled double blinded crossover study. Design: Crossover Randomized Control Trial Setting: Academically affiliated private infertility centers Subjects: Female IVF patients of all ages who are willing to be randomized to treatment and, in either IVF treatment, frozen embryo cycles (FET) or donor IVF cycles (D-IVF), 5 days before ET, have inadequate endometrial thickness. Interventions: Subjects receive transvaginally, utilizing an insemination catheter, 2 slow intrauterine lavages with CSF-1 (Neupogen or generic, 300ug in 1 ml) 5 and 3 days, respectively, before embryo transfer and controls receive 1 ml of saline instead. Patients who do not become pregnant will after one month washout times continue treatment in the opposite study arm if they so choose and if they have remaining embryos. Main Outcome Measures: Number of patients reaching embryo transfer with adequate endometrial thickness of at least 7mm. Second Outcome Measures: Implantation and pregnancy rates.. Statistical and Power considerations: This is a Randomized Controlled Trial (RCT) with two study arms and panned crossover. Patients will be randomly assigned to Study group A or B according to a computer generated randomization table with 50:50 distributions. The study will test the null hypothesis that there is no difference in the transfer rates between the two groups. Transfer is only possible if the endometrial thickness reaches 7 mm or more. Order of treatment ab v ba will be added to the models as a separate factor and each phase will be analyzed as separate treatment strata. The investigators are planning a study of independent cases and controls with 1 control per case. Prior data indicate that the transfer rate among controls is \< 1%. If the true transfer rate for experimental subjects is 25%, the investigators will need to study 38 experimental subjects and 38 control subjects to be able to reject the null hypothesis that the transfer rates for experimental and control subjects are equal with probability (power) 0.8. The Type I error probability associated with this test of this null hypothesis is 0.05. We will use a continuity-corrected chi-squared statistic or Fisher's exact test to evaluate this null hypothesis. There will be a planned interim analysis after 20 participants have completed the trial and if significant effects are observed the trial may be terminated at that time. The power to detect a difference in this interim analysis is only 42.6%.

Interventions

DRUGG-CSF

One infusion of G-CSF 300 units administered by intrauterine infusion

DRUGSaline

One intrauterine saline infusions of 1 cc

Sponsors

Foundation for Reproductive Medicine
CollaboratorOTHER
Center for Human Reproduction
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
21 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* Patient's preparing for invitro fertilization and embryo transfer with endometrial growth of less than 7 mm, unresponsive to standard treatment

Exclusion criteria

* Sickle Cell disease * Renal insufficiency * Upper respiratory infection or Pneumonia * Chronic Neutropenia * Known Past or present malignancy

Design outcomes

Primary

MeasureTime frameDescription
Endometrial ThicknessDay of embryo transferThickness of the endometrium on the day of embryo transfer

Secondary

MeasureTime frameDescription
Implantation Rate28 days after embryo transferNumber of gestational sacs per number of embryos transferred in each treatment group

Countries

United States

Participant flow

Recruitment details

All patients presenting for embryos transfer between October 3, 2010, and January 1, 2013, were offered participation in the trial. A total of 419 eligible patients were offered participation: Only 12 patients consented to participate in this study,(129 addtional patient participated in the NCT01202656 study) and 278 declined.

Pre-assignment details

The principal reasons for refusal to participate were ''lack of interest'' and technical difficulties in presenting in timely fashion for the treatment to the center. Women with renal disease, sickle cell disease, or a history of malignancy were considered ineligible. No consenting patient was excluded from participation for medical reasons.

Participants by arm

ArmCount
G-CSF Then Saline
G-CSF 300 units administered by trans-cervical infusion one time on day of hCG trigger for Ovulation then Saline administered by trans-cervical infusion one time on day of hCG trigger for ovulation
6
Saline Then G-CSF
Saline administered by trans-cervical infusion one time on day of hCG trigger for ovulation then G-CSF 300 units administered by trans-cervical infusion one time on day of hCG trigger for Ovulation
6
Total12

Baseline characteristics

CharacteristicG-CSF Then SalineSaline Then G-CSFTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
6 Participants6 Participants12 Participants
Age, Continuous39.79 Years
STANDARD_DEVIATION 5.13
39.38 Years
STANDARD_DEVIATION 6.03
39.59 Years
STANDARD_DEVIATION 5.56
Endometrial Thickness5.6 mm
STANDARD_DEVIATION 0.22
6.2 mm
STANDARD_DEVIATION 0.69
5.8 mm
STANDARD_DEVIATION 0.46
FSH8.64 mIU/mL
STANDARD_DEVIATION 3.92
8.27 mIU/mL
STANDARD_DEVIATION 4.01
8.46 mIU/mL
STANDARD_DEVIATION 3.95
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
1 Participants0 Participants1 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
5 Participants6 Participants11 Participants
Sex: Female, Male
Female
6 Participants6 Participants12 Participants
Sex: Female, Male
Male
0 Participants0 Participants0 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 80 / 7
serious
Total, serious adverse events
0 / 80 / 7

Outcome results

Primary

Endometrial Thickness

Thickness of the endometrium on the day of embryo transfer

Time frame: Day of embryo transfer

ArmMeasureValue (MEAN)Dispersion
G-CSFEndometrial Thickness11.3 mmStandard Deviation 3.1
SalineEndometrial Thickness7.8 mmStandard Deviation 0.8
p-value: 0.67ANCOVA
Secondary

Implantation Rate

Number of gestational sacs per number of embryos transferred in each treatment group

Time frame: 28 days after embryo transfer

Population: Presuming an implantation rate of 10% and anticipating a 10% increase to 20% with treatment, about 200 embryos transferred in each study arm would be needed for 80% power and alpha of 0.05.

ArmMeasureValue (NUMBER)
G-CSFImplantation Rate1 Gestational sacs
SalineImplantation Rate2 Gestational sacs
Comparison: Study was closed due to insufficient recruitmentp-value: 0.74Chi-squared, Corrected

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026